PL3004079T3 - Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma - Google Patents
Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gammaInfo
- Publication number
- PL3004079T3 PL3004079T3 PL14727562T PL14727562T PL3004079T3 PL 3004079 T3 PL3004079 T3 PL 3004079T3 PL 14727562 T PL14727562 T PL 14727562T PL 14727562 T PL14727562 T PL 14727562T PL 3004079 T3 PL3004079 T3 PL 3004079T3
- Authority
- PL
- Poland
- Prior art keywords
- gamma secretase
- pyrimidine compounds
- secretase modulators
- modulators
- pyrimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1350685 | 2013-06-04 | ||
| EP14727562.2A EP3004079B1 (en) | 2013-06-04 | 2014-06-03 | Pyrimidine compounds and their use as gamma secretase modulators |
| PCT/EP2014/061503 WO2014195323A1 (en) | 2013-06-04 | 2014-06-03 | Pyrimidine compounds and their use as gamma secretase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3004079T3 true PL3004079T3 (pl) | 2018-07-31 |
Family
ID=50877325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14727562T PL3004079T3 (pl) | 2013-06-04 | 2014-06-03 | Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9439904B2 (pl) |
| EP (1) | EP3004079B1 (pl) |
| JP (1) | JP6368777B2 (pl) |
| CN (1) | CN105263923B (pl) |
| DK (1) | DK3004079T3 (pl) |
| ES (1) | ES2665421T3 (pl) |
| NO (1) | NO3004079T3 (pl) |
| PL (1) | PL3004079T3 (pl) |
| WO (1) | WO2014195323A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018007331A1 (en) * | 2016-07-08 | 2018-01-11 | F. Hoffmann-La Roche Ag | Fused pyrimidine derivatives |
| CN108191776A (zh) * | 2018-01-22 | 2018-06-22 | 无锡富泽药业有限公司 | 一种尿嘧啶的绿色生产工艺 |
| WO2020247707A1 (en) * | 2019-06-05 | 2020-12-10 | Chunyu Wang | SYSTEMS AND METHOD FOR INHIBITING γ-SECRETASE PRODUCTION OF AMYLOID-β PEPTIDES |
| US12297244B2 (en) | 2019-06-05 | 2025-05-13 | Rensselaer Polytechnic Institute | Systems and methods for inhibiting γ-secretase production of amyloid-β peptides |
| CN110372603A (zh) * | 2019-06-24 | 2019-10-25 | 南京普锐达医药科技有限公司 | 一种2-氯-5-氟-6-乙基嘧啶的合成方法 |
| CN113149977A (zh) | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
| IL306008A (en) | 2021-03-23 | 2023-11-01 | Halia Therapeutics Inc | Pyrimidine derivatives are useful as LRRK2 kinase inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002528499A (ja) * | 1998-10-29 | 2002-09-03 | ブリストル−マイヤーズ スクイブ カンパニー | Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物 |
| ITMI20030312A1 (it) | 2003-02-21 | 2004-08-22 | Chiesi Farma Spa | Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer. |
| WO2005013985A1 (en) | 2003-08-07 | 2005-02-17 | Merck Sharp & Dohme Limited | Treatment for alzheimer's disease and related conditions |
| DE602004023762D1 (de) | 2003-12-03 | 2009-12-03 | Merck Sharp & Dohme | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren |
| TWI335816B (en) | 2004-05-26 | 2011-01-11 | Eisai R&D Man Co Ltd | Cinnamide compound |
| WO2007053452A1 (en) * | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007125364A1 (en) | 2006-04-26 | 2007-11-08 | Merck Sharp & Dohme Limited | Piperidines and related compounds for treatment of alzheimer’s disease |
| JPWO2007135969A1 (ja) | 2006-05-19 | 2009-10-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア系−シンナミド誘導体 |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| US8183276B2 (en) | 2007-02-08 | 2012-05-22 | Christian Fischer | Therapeutic agents |
| JP2010518083A (ja) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | ピペリジン誘導体 |
| WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS |
| EP2185522A1 (en) | 2007-08-06 | 2010-05-19 | Schering Corporation | Gamma secretase modulators |
| KR101244517B1 (ko) | 2008-01-11 | 2013-03-18 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타에 대한 조절제 |
| EP2257541B1 (en) | 2008-02-22 | 2013-08-14 | F. Hoffmann-La Roche AG | Modulators for amyloid beta |
| JP5502089B2 (ja) * | 2008-10-09 | 2014-05-28 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβのモジュレーター |
| MX2011004680A (es) | 2008-11-06 | 2011-05-25 | Astrazeneca Ab | Moduladores de beta amiloide. |
| KR101293421B1 (ko) | 2008-11-10 | 2013-08-05 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 감마 분비효소 조절제 |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| UY32622A (es) | 2009-05-12 | 2010-12-31 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) |
| CA2778517A1 (en) | 2009-07-15 | 2011-01-20 | Janssen Pharmaceuticals, Inc. | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| CA2784769A1 (en) | 2010-01-15 | 2011-07-21 | Janssen Pharmaceuticals, Inc. | Novel substituted triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| TW201206946A (en) | 2010-07-15 | 2012-02-16 | Bristol Myers Squibb Co | Compounds for the reduction of beta-amyloid production |
-
2014
- 2014-06-03 US US14/895,528 patent/US9439904B2/en not_active Expired - Fee Related
- 2014-06-03 JP JP2016517275A patent/JP6368777B2/ja not_active Expired - Fee Related
- 2014-06-03 CN CN201480032083.0A patent/CN105263923B/zh not_active Expired - Fee Related
- 2014-06-03 NO NO14727562A patent/NO3004079T3/no unknown
- 2014-06-03 DK DK14727562.2T patent/DK3004079T3/en active
- 2014-06-03 ES ES14727562.2T patent/ES2665421T3/es active Active
- 2014-06-03 WO PCT/EP2014/061503 patent/WO2014195323A1/en not_active Ceased
- 2014-06-03 PL PL14727562T patent/PL3004079T3/pl unknown
- 2014-06-03 EP EP14727562.2A patent/EP3004079B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NO3004079T3 (pl) | 2018-06-16 |
| DK3004079T3 (en) | 2018-04-16 |
| CN105263923A (zh) | 2016-01-20 |
| ES2665421T3 (es) | 2018-04-25 |
| US20160129002A1 (en) | 2016-05-12 |
| JP2016520637A (ja) | 2016-07-14 |
| JP6368777B2 (ja) | 2018-08-01 |
| WO2014195323A1 (en) | 2014-12-11 |
| US9439904B2 (en) | 2016-09-13 |
| EP3004079A1 (en) | 2016-04-13 |
| CN105263923B (zh) | 2017-06-23 |
| EP3004079B1 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201600028YA (en) | Substituted aminopyrimidine compounds and methods of use | |
| IL245733A0 (en) | aplnr modulators and their uses | |
| IL240788A0 (en) | Heterocyclic compounds and their uses | |
| PL3381917T3 (pl) | Związki imidazopirydynowe i i ch zastosowania | |
| GB201317286D0 (en) | Composition and Use | |
| HUE047592T2 (hu) | Szubsztituált 2-azabiciklusok és alkalmazásuk orexin receptor modulátorokként | |
| EP3083606A4 (en) | Pyrimidines and use thereof | |
| PL3004079T3 (pl) | Związki pirymidyny i ich zastosowanie jako modulatorów sekretazy gamma | |
| IL244817B (en) | Transmuted pyrimidine compounds and their use as syk inhibitors | |
| IL243957A0 (en) | Formulations containing gamma secretase modulators | |
| SG11201604755QA (en) | Substituted dihydro-benzimidazole compounds as ror gamma modulators | |
| GB201309180D0 (en) | Compounds and Their Uses | |
| IL240177A0 (en) | Converted chromium-6-yloxy-cycloalkanes and their use as drugs | |
| DK3004080T3 (da) | Triazolforbindelser og deres anvendelse som gamma-sekretase-modulatorer | |
| GB201314610D0 (en) | Compounds and their uses | |
| GB201306248D0 (en) | Compounds and their uses | |
| GB201313605D0 (en) | Novel compounds and their use | |
| AU2013902560A0 (en) | Heterocyclic compounds and their use | |
| EP3013851A4 (en) | MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE | |
| GB201320161D0 (en) | Compounds and their uses | |
| GB201322467D0 (en) | Composition and use | |
| GB201309248D0 (en) | Compounds and combinations |